- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Main roads to melanoma ; volume:7 ; number:1 ; day:14 ; month:10 ; year:2009 ; pages:1-17 ; date:12.2009
Journal of translational medicine ; 7, Heft 1 (14.10.2009), 1-17, 12.2009
- Urheber
-
Palmieri, Giuseppe
- Beteiligte Personen und Organisationen
-
Capone, Mariaelena
Ascierto, Maria Libera
Gentilcore, Giusy
Stroncek, David F.
Casula, Milena
Sini, Maria Cristina
Palla, Marco
Mozzillo, Nicola
Ascierto, Paolo A.
SpringerLink (Online service)
- DOI
-
10.1186/1479-5876-7-86
- URN
-
urn:nbn:de:1111-2016041433885
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Palmieri, Giuseppe
- Capone, Mariaelena
- Ascierto, Maria Libera
- Gentilcore, Giusy
- Stroncek, David F.
- Casula, Milena
- Sini, Maria Cristina
- Palla, Marco
- Mozzillo, Nicola
- Ascierto, Paolo A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Melanoma: A model for testing new agents in combination therapies
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Melanoma: A model for testing new agents in combination therapies
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Melanoma: A model for testing new agents in combination therapies
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017